Mineralys Therapeutics Files 8-K
Ticker: MLYS · Form: 8-K · Filed: Feb 4, 2025 · CIK: 1933414
Sentiment: neutral
Topics: 8-K, reporting
Related Tickers: MLYS
TL;DR
MLYS filed a routine 8-K, no major news.
AI Summary
Mineralys Therapeutics, Inc. filed an 8-K on February 4, 2025, to report on other events and financial statements. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates routine corporate reporting by Mineralys Therapeutics, Inc. without disclosing any immediate material changes or events.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report with no disclosed material events or changes, indicating low immediate risk.
Key Players & Entities
- Mineralys Therapeutics, Inc. (company) — Registrant
- February 4, 2025 (date) — Date of earliest event reported
- 150 N. Radnor Chester Road, Suite F200, Radnor, Pennsylvania 19087 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Mineralys Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of February 4, 2025.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is February 4, 2025.
What is the principal executive office address for Mineralys Therapeutics, Inc.?
The principal executive office address is 150 N. Radnor Chester Road, Suite F200, Radnor, Pennsylvania 19087.
What is the company's state of incorporation?
The company's state of incorporation is Delaware.
Does this filing disclose any specific new material events or financial results?
No, this filing appears to be a routine report and does not disclose specific new material events or detailed financial results beyond standard reporting categories.
Filing Stats: 629 words · 3 min read · ~2 pages · Grade level 11.2 · Accepted 2025-02-04 08:05:17
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share MLYS The Nasdaq Stock Marke
Filing Documents
- mlys-20250204.htm (8-K) — 28KB
- mlys202502048kex991.htm (EX-99.1) — 16KB
- a1a.jpg (GRAPHIC) — 5KB
- 0001933414-25-000006.txt ( ) — 185KB
- mlys-20250204.xsd (EX-101.SCH) — 2KB
- mlys-20250204_lab.xml (EX-101.LAB) — 23KB
- mlys-20250204_pre.xml (EX-101.PRE) — 13KB
- mlys-20250204_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On February 4, 2025, Mineralys Therapeutics, Inc. (the Company) issued a press release announcing that it has completed enrollment in its Explore-CKD Phase 2 trial evaluating the efficacy and safety of lorundrostat for the treatment of hypertension in subjects with chronic kidney disease (CKD) and albuminuria, despite receiving stable treatment with an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB) and an SGLT2 inhibitor. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing.
01. Other Events
Item 8.01. Other Events. On February 4, 2025, the Company announced that it has completed enrollment in its Explore-CKD Phase 2 trial evaluating the efficacy and safety of lorundrostat for the treatment of hypertension in subjects with CKD and albuminuria, despite receiving stable treatment with an ACEi or an ARB and an SGLT2 inhibitor.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release Issued on February 4, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 4, 2025 MINERALYS THERAPEUTICS, INC. By: /s/ Adam Levy Name: Adam Levy Title: Chief Financial Officer and Secretary